Abstracts tagged "systemic necrotizing vasculitis"

Abstract Number: 1716 • 2019 ACR/ARP Annual Meeting
Poor-Prognosis Factors of Systemic Vasculitides with Gastrointestinal Involvement: Data from a Large Retrospective Study
Segolene Gendreau¹, Benjamin Thoreau ², François Maurier ³, Tiphaine Goulenok ¹, Laure Frumholtz ¹, Arsène Mékinian ⁴, Saskia Oro ⁵, Charlotte Bernigaud ⁵, Alexandra Audemard ¹, Maxime Samson ⁶, Antoine Gaillet ¹, Romain Sonneville ¹, Jean-Benoit Arlet ¹, Adrien Mirouse ¹, Jean-Emmanuel Kahn ⁷, Aurélie Hummel ¹, Thomas Pires ⁸, Wendy Jourde ⁸, Eric Hachulla ⁹, Pierre-Louis Carron ¹⁰, Cécile-Audrey Durel ¹¹, Francoise Sarrot-Reynauld ¹², Nathalie Tieulie ¹³, Elisabeth Diot ¹⁴, Christian Agard ¹⁵, Guillaume Armengol ¹⁶, Alice Berezne ¹⁷, Christophe Deligny ¹⁸, Fleur Cohen ¹, Stanislas Faguer ¹⁹, Guillaume Le Guenno ²⁰, Mohamed Hamidou ¹⁵, Loïc Guillevin ²¹ and Benjamin Terrier ²¹, ¹APHP, Paris, France, ²CHU Tours, Tours, France, ³Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ⁴Hôpital Saint-Antoine, APHP, Paris, Paris, France, ⁵APHP, Creteil, France, ⁶Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ⁷APHP, Boulogne Billancourt, France, ⁸CHU Bordeaux, Bordeaux, France, ⁹CHU Lille, Lille, France, ¹⁰Grenoble, Grenoble, France, ¹¹Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹²CHU Grenoble, Grenoble, France, ¹³University Hospital of Nice, Nice, France, ¹⁴APHP, Tours, France, ¹⁵CHU Nantes, Nantes, France, ¹⁶CHU Rouen, Rouen, France, ¹⁷CH Annecy Genevois, Annecy, France, ¹⁸CHU Martinique, Fort de France, France, ¹⁹CHU Toulouse, Toulouse, France, ²⁰CHU Clermont Ferrand, Clermont Ferrand, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Gastrointestinal (GI) involvement was described as a poor-prognosis factor of systemic necrotizing vasculitides. However, the prognostic impact of GI involvement may vary according to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].